011070.KS · Korea Exchange KOSPI Market
LG Innotek Co Ltd
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$8.91bnFinancials dated 31 December 2025Price dated 15 September 2026
Core valuation
Calculation inputs
- Trailing earnings
- US$483.44m
- Latest-quarter run-rate earnings
- US$494.76m
- Latest fiscal-year earnings
- US$248.79m
- Trailing revenue
- US$17.53bn
- Latest-quarter run-rate revenue
- US$16.12bn
- Latest fiscal-year revenue
- US$15.96bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- FPA · First Trust Asia Pacific Ex-Japan AlphaDEX® Fund2.54% weight · Holdings dated 30 June 2026
- AVEE · Avantis Emerging Markets Small Cap Equity ETF1.53% weight · Holdings dated 31 May 2026
- AVES · Avantis Emerging Markets Value ETF1.39% weight · Holdings dated 31 May 2026
- FDT · First Trust Developed Markets Ex-US AlphaDEX® Fund1.26% weight · Holdings dated 30 June 2026
- ICOW · Pacer Developed Markets International Cash Cows 100 ETF0.65% weight · Holdings dated 30 April 2026
- JPIN · JPMorgan Diversified Return International Equity ETF0.63% weight · Holdings dated 30 April 2026
- AVXC · Avantis Emerging Markets Ex-China Equity ETF0.44% weight · Holdings dated 31 May 2026
- AVSE · Avantis Responsible Emerging Markets Equity ETF0.39% weight · Holdings dated 31 May 2026
- EEMS · iShares MSCI Emerging Markets Small-Cap ETF0.33% weight · Holdings dated 21 August 2026
- AVEM · Avantis Emerging Markets Equity ETF0.29% weight · Holdings dated 31 May 2026
Sources and limitations
Financial inputs are attributed to OpenDART statutory filings. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 31 December 2025. Informational research, not investment advice.